Highlights from the 12th World Conference on Lung Cancer - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA; David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN; David Jackman, MD, Dana-Farber Cancer Institute, Boston, MD.

12th World Conference on Lung Cancer: Updates in the Management of Early Stage Non-Small Cell Lung Cancer (NSCLC) - CME
Chandra Belani, MD, Penn State Cancer Center, Hershey, PA

12th World Conference on Lung Cancer: Advances in the Management of Advanced NSCLC: Are We Making Progress? - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

12th World Conference on Lung Cancer: Malignant Pleural Mesothelioma Updates - CME
David Jackman, MD, Dana-Farber Cancer Institute, Boston, MA

12th World Conference on Lung Cancer: Advances in the Management of Small-Cell Lung Cancer (SCLC) - CME
David Spigel, MD, The Sarah Cannon Research Institute, Nashville, TN

Folic Acid and Vitamin B12 Increase Risk of Cancer in Patients with Heart Disease (11/19/2009)
Researchers from Norway have reported that folic acid and B12 supplements in patients with ischemic heart disease increase the risk of cancer and all-cause mortality. The details of this study appeared in the November 18, 2009 issue of the Journal of the American Medical Society.

Continuous Daily Sutent® Palliative in Patients with Relapsed or Refractory Advanced NSCLC (11/5/2009)
Researchers from several U.S. and Spanish medical centers have reported that single-agent daily Sutent® (sunitinib) was associated with a 25% disease control rate in patients with previously treated advanced non–small cell lung cancer (NSCLC). The details of this study appeared in the November 4, 2009 issue of the British Journal of Cancer.

Amrubicin® and Paraplatin® Active and Tolerable in Elderly Patients with SCLC (10/22/2009)
Researchers from Japan have reported Amrubicin®, a new synthetic anthracycline, combined with Paraplatin® (carboplatin) resulted in an 89% overall response rate (ORR) in elderly patients with small cell lung cancer (SCLC). The details of this report appeared in an early online publication in the Annals of Oncology on October 13, 2009.

Maintenance Tarceva® Improves Overall Survival of Patients with Advanced NSCLC (9/28/2009)
Researchers affiliated with the SATURN study have reported that maintenance therapy with Tarceva® (erlotinib) improves overall survival (OS) in patients with advanced non–small cell lung cancer (NSCLC) who have no evidence of disease progression after four cycles of platinum-based induction therapy. The details of this randomized trial were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.

Iressa® Improves Progression-free Survival over Standard Chemotherapy in Patients with NSCLC with EGFR Mutations (9/28/2009)
Researchers from Japan have reported that Iressa® (gefitinib) alone improves outcomes of patients with non–small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR) mutations compared with patients receiving Paraplatin® (carboplatin) and Taxol® (paclitaxel). The details of this study were presented at the Joint ECCO 15 – 34^th ESMO Multidisciplinary Congress in Berlin, September 20-24, 2009.